Evaluation of a new biphasic calcium phosphate for maxillary sinus floor elevation: Micro-CT and histomorphometrical analyses

Clin Oral Implants Res. 2018 May;29(5):488-498. doi: 10.1111/clr.13146. Epub 2018 Apr 11.

Abstract

Objectives: Synthetic biphasic calcium phosphate (BCP) with a hydroxyapatite/ß-tricalcium phosphate (HA/ß-TCP) ratio of 60/40 (BCP60/40) is successfully used as alternative for autologous bone in patients undergoing maxillary sinus floor elevation (MSFE) for dental implant placement. A high percentage of HA in BCP60/40 may hamper efficient scaffold remodeling. Osteogenesis and neovascularization are pivotal in effective bone regeneration. We aimed to investigate whether differences exist in osteogenic and/or vasculogenic potential of BCP60/40 and BCP20/80 in patients undergoing MSFE.

Materials and methods: Twenty patients undergoing MSFE were treated with BCP60/40 (n = 10) or BCP20/80 (n = 10). Bone and graft volumes were determined by micro-computed tomography and histomorphometrical analysis of biopsies of the augmented region. Osteoid volumes, number of osteoclasts, and blood vessels were determined by histomorphometrical analysis. The biopsies were taken 6.5 months (26 weeks) postoperatively prior to dental implant placement.

Results: Bone and osteoid volumes were 9.7% and 0.8% higher at the most cranial side of the BCP20/80 biopsies compared to the BCP60/40 biopsies. Graft volumes, number of osteoclasts, and blood vessels were similar in both groups.

Conclusions: BCP20/80 showed enhanced osteogenic potential in patients undergoing MSFE compared to BCP60/40, due to either a faster bone remodeling rate or an earlier start of bone formation in BCP20/80-treated patients, suggesting that a higher TCP content positively contributes to the bone remodeling rate. Therefore, BCP20/80 might perform better, at least in the short term, as a scaffold for bone augmentation in the MSFE model than BCP60/40 as more bone is formed, and more osteoid is deposited at the cranial side in BCP20/80-treated patients compared to BCP60/40-treated patients. However, catch-up of BCP60/40 in the long term cannot be ruled out.

Keywords: bone regeneration; bone substitutes; clinical research; clinical trials; guided tissue regeneration; morphometric analysis; sinus floor elevation.

MeSH terms

  • Alveolar Process / diagnostic imaging*
  • Alveolar Process / pathology
  • Alveolar Process / surgery
  • Bone Substitutes / therapeutic use*
  • Female
  • Humans
  • Hydroxyapatites / therapeutic use*
  • Male
  • Middle Aged
  • Radiography, Dental
  • Sinus Floor Augmentation / methods*
  • Tissue Scaffolds
  • X-Ray Microtomography

Substances

  • Bone Substitutes
  • Hydroxyapatites
  • hydroxyapatite-beta tricalcium phosphate